The pursuit of outperformance leads many investors to carefully choose individual stocks. Picking the right ones can be a game-changer for growing your wealth.
After finishing at $15.34 in the prior trading day, Mineralys Therapeutics Inc (NASDAQ: MLYS) closed at $14.47, down -5.67%. In other words, the price has decreased by -$5.67 from its previous closing price. On the day, 1.17 million shares were traded. MLYS stock price reached its highest trading level at $15.28 during the session, while it also had its lowest trading level at $14.38.
Ratios:
Our goal is to gain a better understanding of MLYS by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 15.12 and its Current Ratio is at 15.12. In the meantime, Its Debt-to-Equity ratio is 0.00 whereas as Long-Term Debt/Eq ratio is at 0.00.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Jefferies on June 11, 2025, initiated with a Hold rating and assigned the stock a target price of $15.
On July 10, 2024, H.C. Wainwright started tracking the stock assigning a Buy rating and target price of $30.
On April 02, 2024, Goldman started tracking the stock assigning a Buy rating and target price of $30.Goldman initiated its Buy rating on April 02, 2024, with a $30 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Aug 13 ’25 when Rodman David Malcom sold 11,365 shares for $12.93 per share. The transaction valued at 146,987 led to the insider holds 92,891 shares of the business.
Rodman David Malcom bought 11,365 shares of MLYS for $146,987 on Aug 13 ’25. On Jul 30 ’25, another insider, Levy Adam Scott, who serves as the CFO and Secretary of the company, sold 59,925 shares for $14.76 each. As a result, the insider received 884,372 and left with 132,934 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, MLYS now has a Market Capitalization of 959291584 and an Enterprise Value of 634375296.
Stock Price History:
The Beta on a monthly basis for MLYS is -0.30, which has changed by 0.29892278 over the last 52 weeks, in comparison to a change of 0.14064062 over the same period for the S&P500. Over the past 52 weeks, MLYS has reached a high of $18.38, while it has fallen to a 52-week low of $8.24. The 50-Day Moving Average of the stock is 2.77%, while the 200-Day Moving Average is calculated to be 10.09%.
Shares Statistics:
The stock has traded on average 798.84K shares per day over the past 3-months and 959580 shares per day over the last 10 days, according to various share statistics. A total of 65.73M shares are outstanding, with a floating share count of 42.70M. Insiders hold about 35.59% of the company’s shares, while institutions hold 73.87% stake in the company. Shares short for MLYS as of 1753920000 were 6996921 with a Short Ratio of 8.76, compared to 1751241600 on 7667206. Therefore, it implies a Short% of Shares Outstanding of 6996921 and a Short% of Float of 14.19.
Earnings Estimates
The market rating for Mineralys Therapeutics Inc (MLYS) is a result of the insights provided by 7.0 analysts actively involved in the assessment.The consensus estimate for the next quarter is -$0.65, with high estimates of -$0.48 and low estimates of -$0.82.
Analysts are recommending an EPS of between -$2.41 and -$3.01 for the fiscal current year, implying an average EPS of -$2.67. EPS for the following year is -$2.99, with 7.0 analysts recommending between -$2.11 and -$4.3.
